Phase 1 Study of CLN-619 Alone or with Pembrolizumab in Advanced Solid Tumors, Including NSCLC, Cervical, Endometrial, Ovarian, Breast, and Gastrointestinal Cancers

The primary objective of this study is to evaluate the safety and tolerability of **CLN-619** when administered alone or in combination with **pembrolizumab** in patients with advanced **solid tumors**. This is clinically relevant as it aims to determine the potential of CLN-619 as a therapeutic option for various cancers, including **Non-Small Cell Lung Cancer**, **Cervical Cancer**, **Endometrial Cancer**, **Ovarian Cancer**, **breast cancer**, and **gastrointestinal cancer**. The study seeks to establish a safe dosage range and assess any adverse effects, which is crucial for the development of effective cancer treatments.

The clinical trial involves a total of **300 participants** diagnosed with various **solid tumors**, including **Non-Small Cell Lung Cancer**, **Cervical Cancer**, **Endometrial Cancer**, **Ovarian Cancer**, **breast cancer**, and **gastrointestinal cancer**. The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process for the trial population is not explicitly described, and no principal inclusion criteria are provided. The study aims to encompass a broad demographic to ensure comprehensive data collection across different cancer types.

The clinical trial is a **Phase 1** open-label, first-in-human, multi-center study designed to evaluate the safety, tolerability, and preliminary efficacy of CLN-619, administered alone or in combination with pembrolizumab, in patients with advanced **solid tumors**. The study employs a dose escalation and dose expansion approach to determine the optimal dosing regimen. The trial is expected to commence on November 1, 2022, and conclude by December 30, 2026. Participants will be involved in the study for varying durations depending on their response to the treatment and the specific phase of the trial they are enrolled in.

The trial includes several key visits: an initial **screening visit** to assess eligibility, multiple follow-up visits to monitor safety and efficacy, and an end-of-study visit to evaluate overall outcomes. The screening visit will involve a comprehensive assessment of the participant's medical history, current health status, and specific inclusion criteria related to the types of cancers being studied, such as **Non-Small Cell Lung Cancer**, **Cervical Cancer**, **Endometrial Cancer**, **Ovarian Cancer**, **Breast Cancer**, and **Gastrointestinal Cancer**. Follow-up visits will be scheduled at regular intervals to collect data on the participant's response to the treatment and any adverse events. The end-of-study visit will provide a final evaluation of the participant's health status and the overall impact of the treatment.

Participants may be withdrawn from the study early if they experience significant adverse effects, if their disease progresses despite treatment, or if they choose to withdraw consent. The study is designed to ensure participant safety and the integrity of the data collected, with all procedures conducted in accordance with ethical guidelines and regulatory requirements. The trial's randomized, controlled design, although open-label, allows for a robust assessment of the investigational treatment's potential benefits and risks in the target population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used alongside the experimental medication. The absence of such information suggests that the focus is solely on the experimental treatment, although this cannot be confirmed without further details.

Details regarding the **participant compliance monitoring** and specific **dosing schedules** are not included in the provided data. The lack of this information indicates that the trial documentation may require additional input to ensure comprehensive understanding and adherence to the study protocol.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of November 1, 2022, and an estimated end date of December 30, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve standard methodologies appropriate for a Phase 1 study. These may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure efficacy. The schedule for measuring and collecting data will be aligned with the trial's objectives and duration, ensuring comprehensive analysis of the treatment's impact. The analysis will be conducted using scientifically accepted methods to ensure the reliability and validity of the results.